Novo Nordisk announced it would change its name to ‘Novo’, dropping ‘Nordisk’ from its corporate identity. This rebranding aims to modernize the Danish pharmaceutical company’s image among the general public. The company’s stock price fell following the announcement. The group is betting on this strategic shift to regain market share against rival Eli Lilly in the GLP-1 drugs sector. This move reflects the company’s desire to adapt culturally and commercially to changing market dynamics.
Source: Read the original article
